This results in a long half-life (approximately 7 days), making it suitable for once-weekly subcutaneous injection
Cell Metab 34(7):10541063 Secher A et al (2014) The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Data were analyzed using Open Office Calc (Apache), graphed using PRISM (GraphPad) and clustered using Multi-experiment Viewer (MeV)
An online search utilizing the PubMed search engine was carried out using the MeSH terms Diabetes Mellitus, Hyperglycemia, Diabetes Complications, Hypoglycemic Agents, Glucagon-Like Peptide-1 Receptor Agonists, Glycoside Hydrolase Inhibitors, Acarbose, Metformin, Dipeptidyl-Peptidase IV Inhibitors, Sodium-Glucose Transporter 2 Inhibitors, Drug-Related Side Effects and Adverse Reactions, Gastrointestinal Diseases, Gastroparesis, Gastric Emptying, Dysbiosis, Gastrointestinal Microbiome, Microbiota, Constipation, Diarrhea, Nausea, Vomiting, Gastrointestinal Agents
According to the Employee Benefit Research Institute, simulation modeling indicates that expanding GLP1 coverage can raise employer health premiums by 6% to nearly 14% annually, depending on how widely the drugs are made available and how consistently members remain on therapy
But the growing number of older women who are losing significant amounts of weight while also dealing with the impacts of menopause could create future bone health problems, according to Wendy Kohrt, a University of Colorado Anschutz School of Medicine expert on bone health